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. Nordmann
Hopital de Bicetre, South Paris Med. School, Paris, France
Carbapenem-hydrolyzing ß-lactamases are the most powerful
-lactamases being able to hydrolyse almost all ß-lactams. They
re mostly of the KPC, VIM, IMP, NDM and OXA-48 type in Enter-
bacteriaceae. Detection of infected patients relies on detection of
arbapenemase producers from infected sites. Rapid biochemical
dentiﬁcation of carbapenemase producers (NP Rapid Carba test)
s now available and subsequent molecular-based techniques may
dentify the molecular type of carbapenemase genes. Detection of
arriers is made ﬁrst by using screening culture media such as the
upercarba medium which is the latest developped.
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he role of antimicrobial stewardship in curbing Carbapenem
esistance
. Lye
Communicable Disease Centre, Tan Tock Seng Hospital Singapore,
ingapore, Singapore
Carbapenem resistance in Acinetobacter baumannii and Enter-
bacteriaceae ranks as one of the most serious and challenging
ublic health problem worldwide. Antibiotic treatment option is
xtremely limited and antibiotic development pipeline for gram-
egative bacteria is unpromising. While KPC beta-lactamases are
urrently reported in North America and Europe, and limited coun-nfectious Diseases 16S (2012) e2–e157 e27
tries in the Far East, OXA carbapenemases in A. baumannii and New
Delhimetallo-beta-lactamase (NDM-1) in Enterobacteriaceae have
disseminated globally. Control measures for multidrug-resistant
(MDR) organisms comprise a combination of infection control and
antimicrobial stewardship program (ASP). Horizontal transmis-
sion of gram-negative bacteria with the exception of A. baumannii
is less recognized until recently. Antibiotic selection pressure is
thought to be more important in the emergence of MDR gram-
negative bacteria. ASP has been successful in containing outbreak
of extended-spectrum beta-lactamase producing Enterobacteri-
aceae and MDR Pseudomonas aeruginosa. Reduction in antibiotic
resistance ingram-negativebacteriahasbeenobservedwith reduc-
tion in use of broad-spectrum antibiotics. Experience with ASP in
containing MDR A.baumannii and KPC Enterobacteriaceae will be
reviewed. The results of 3 years of a comprehensive multi-faceted
multi-disciplinary ASP at Tan Tock Seng Hospital in Singapore will
be shared, where reduction in carbapenem use was associated
with sustained reduction in carbapenem-resistant P. aeruginosabut
not MDR A. baumannii. Rebound in carbapenem overuse has been
associated with emergence of carbapenem-resistant Enterobacte-
riaceae including locally acquired NDM-1.
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The role of infection control in curbing Carbapenem resistance
A. Apisarnthanarak
Thammasat University Hospital, Pratumthani, Thailand
Carbapenem resistant Gram-negative pathogens have become a
threat to many countries in Western Paciﬁc Region. These microor-
ganisms are difﬁcult to treat and pose challenges for control
strategies. Much of the emergence and spread of carbapenem
resistant Gram-negative pathogens can be contributed to the non-
judicious use of broad-spectrum antibiotics and poor infection
control.Onceantimicrobial resistanceemerges, it canhavea signiﬁ-
cant impact onpatientmorbidity andmortality, aswell as increased
health care costs.
Antimicrobial stewardship is a key component of a multi-
faceted approach to preventing the emergence of carbapenem
resistant Gram-negative pathogens. Application of antimicrobial
stewardship to resource-limited setting can be challenging. The
antimicrobial stewardship program at Thammasat University Hos-
pital, which has been associated with appropriateness of antibiotic
use and improved treatment rates, decreased failure rates, and
reduced healthcare-related costs, is an example of this mul-
tifaceted, multidisciplinary approach. The components of our
antimicrobial stewardship program include continuous education,
introduction of the antibiogram, antibiotic guideline, and antibi-
otic prescription forms with an antimicrobial stewardship team
to continuously monitor the consumption of and audit the use
of antibiotics with real-time, bed-side discussion with prescribing
physicians. This antimicrobial stewardship program began in 2004
and appears to have been sustained over a 8-year period. Never-
theless, to sustain or even further improve these results, lasting
and repeated efforts will be needed. Integrating infection control
efforts into educational and antimicrobial stewardship programs
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s warranted. Active infection control program in resource-limited
ettings for carbapenem resistant Gram-negative pathogens may
nclude modiﬁed active surveillance, contact isolation, cohorting
atients with carbapenem resistant Gram-negative pathogens, 5
oment hand hygiene, environmental cleaning, as well as moni-
oring healthcare workers and providing prompt feedback. These
trategies must be modiﬁed to ﬁt the local setting, organizational
ulture, and infrastructure. Intensiﬁed efforts in infection control
rograms and antibiotic stewardship serve as key components
or long-term success. Given the limited information of infec-
ion control for carbapenem resistant Gram-negative pathogens
n resource-limited setting, additional well-designed studies are
eeded to explore various aspects of outcomes of antimicrobial
tewardship and infection control in resource-limited settings.
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olio eradication – Incorporating IPV more broadly
. Vidor
Sanoﬁ Pasteur, Lyons, France
While the oral poliovirus vaccine (OPV) has been an important
ool in moving towards global eradication of poliomyelitis, its con-
inued use is associated with the ongoing emergence of circulating
accine-derived polioviruses (cVDPVs) and the sporadic occur-
ence of vaccine-associated paralytic poliomyelitis (VAPP) cases.
dditionally, sub-optimal andgeographically inconsistent serocon-
ersion rates following OPV administration further confound the
oal of global eradication.
The inactivated poliovirus vaccine (IPV), however, is not asso-
iated with cVDPVs or VAPP, and results in more consistent
ost-vaccination seroconversion rates. With these advantages in
ind, it is clear that IPV can play a vital role in global poliomyeli-
is eradication, but IPV is less straightforward to administer and is
laimed to be more expensive to deploy than OPV. Mixed and com-
ined OPV/IPV schedules can be used to maximize the beneﬁts of
oth vaccines.
TheWHOconsiders that IPVcouldhavean important role toplay
n low- to middle-income countries, where polio is particularly dif-
cult to eradicatedue to the continueduseofOPV. There arevarious
ossibilities, each with its own pros and cons and variable feasibil-
ty, to promote a broader incorporation of IPV in such countries,
ncluding; fractional doses administered intradermally; develop-
ent of new adjuvants for IPV antigens; an intramuscular schedule
ith a reduced number of doses; or the use of whole-cell pertussis
wP), rather than the more expensive acellular pertussis antigens,
n combination with IPV (eg, hexavalent wP-IPV-containing vac-
ines). In addition, the use of standalone IPV following previous
PV doses could also reduce the immunity gap that is present in
any pediatric populations.
The WHO currently envisages the cessation of wild-typeoliovirus circulation by 2014 through use of IPV, followed by con-
inued IPV use to assure and maintain global eradication.
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The evolution of pertussis vaccines and vaccination programs
U. Thisyakorn
Chulalongkorn University, Bangkok, Thailand
Pertussis, sometimes called whooping cough, is a highly conta-
gious disease that remains an important cause of death worldwide,
more particularly in developing countries. Its mortality occurs
largely in infants less than 1 year of age, especially among those
who have not completed their primary vaccinations.
Diphtheria and tetanus toxoids combinedwithwhole cellBorde-
tella pertussis (DTwP) vaccines were developed and licensed during
the 1940s, have been widely used for over 60 years, and have been
central to theWHOExpandedProgramon Immunization (EPI) since
its inception in 1974, leading to considerable impact in controlling
pertussis. However, there are still global disparities with regard to
vaccine use and coverage.
Concerns about the reactogenicity of DTwP vaccines led to
reduced immunization coverage and a subsequent increase in dis-
ease incidence in some countries. This prompted the development
of acellular (aP) pertussis vaccines, which have a considerably bet-
ter safety proﬁle.
Currently, DTaP vaccines – sometimes combined with other
antigens – are used in the national immunization programs
in Canada, the United States, various European countries (eg,
Denmark, France, Germany, Ireland, Italy, Spain, Sweden, UK),
Asia (eg, Japan, South Korea), Australia, Costa Rica, Mexico, South
Africa, and Turkey. National surveillance programs and speciﬁc
studies in Europe and North America have demonstrated that the
licensed aP vaccines, regardless of the number of acellular pertus-
sis components contained therein, have substantial effectiveness
in preventing pertussiswhen used comprehensively among infants
and young children.
Thebroaderdeploymentof aPvaccines andchildhoodcombined
vaccines is of considerable public health interest. Experience with
the use of these vaccines will be presented.
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Pentavalent and hexavalent combination vaccines of today and
tomorrow
S. Madhi
National Institute for Communicable Diseases (NICD), Johannesburg,
South AfricaVaccines are cost-effective public health tools for the preven-
tion and control of infectious diseases. However, disparity in access
to health care remains a major hurdle to accessing life-saving
